Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors Nov 30 Written By Mukul Verma First-in-Human Phase 1 Clinical Trial in Advanced Solid Tumors is Being Conducted by MD Anderson with an Investment from Cancer Focus Fund ─ NectinCFF Mukul Verma
Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors Nov 30 Written By Mukul Verma First-in-Human Phase 1 Clinical Trial in Advanced Solid Tumors is Being Conducted by MD Anderson with an Investment from Cancer Focus Fund ─ NectinCFF Mukul Verma
